BACKGROUND: Understanding the duration of human papillomavirus (HPV) infection may help find suitable end points for vaccine trials and testing intervals in screening studies. We studied genotype-specific infection duration among 2462 women enrolled in the Ludwig-McGill cohort study. METHODS: Cervical specimens collected every 4-6 months were tested by a polymerase chain reaction protocol. Actuarial techniques were used to estimate the duration of HPV infection and to investigate the influence of age, number of sexual partners, and coinfection with multiple HPV types. RESULTS: At enrollment, the prevalence of infection with high-risk HPV types was 10.6%, and the prevalence of infection with low-risk HPV types was 6.1%; incidence rates were 6.1 and 5.0 infections per 1000 women-months, respectively. Prevalent infections took longer to clear than incident infections (mean time to clearance, 18.6 months vs. 13.5 months). The mean duration of incident infection with high- and low-risk HPV varied according to the analytic approach used to measure this variable and showed considerable variation by HPV type (range, 5.1-15.4 months). Age and number of partners did not influence infection duration, whereas coinfection was associated with increased infection duration. The mean duration of HPV-16 monoinfection was 11.0 months, and the mean duration of HPV-16 coinfection was 15.4 months. CONCLUSION: There was considerable variation among HPV types with regard to the duration of infection. Coinfection with multiple types contributed to an increased infection duration.
BACKGROUND: Understanding the duration of human papillomavirus (HPV) infection may help find suitable end points for vaccine trials and testing intervals in screening studies. We studied genotype-specific infection duration among 2462 women enrolled in the Ludwig-McGill cohort study. METHODS: Cervical specimens collected every 4-6 months were tested by a polymerase chain reaction protocol. Actuarial techniques were used to estimate the duration of HPV infection and to investigate the influence of age, number of sexual partners, and coinfection with multiple HPV types. RESULTS: At enrollment, the prevalence of infection with high-risk HPV types was 10.6%, and the prevalence of infection with low-risk HPV types was 6.1%; incidence rates were 6.1 and 5.0 infections per 1000 women-months, respectively. Prevalent infections took longer to clear than incident infections (mean time to clearance, 18.6 months vs. 13.5 months). The mean duration of incident infection with high- and low-risk HPV varied according to the analytic approach used to measure this variable and showed considerable variation by HPV type (range, 5.1-15.4 months). Age and number of partners did not influence infection duration, whereas coinfection was associated with increased infection duration. The mean duration of HPV-16 monoinfection was 11.0 months, and the mean duration of HPV-16 coinfection was 15.4 months. CONCLUSION: There was considerable variation among HPV types with regard to the duration of infection. Coinfection with multiple types contributed to an increased infection duration.
Authors: K L Kotloff; S S Wasserman; K Russ; S Shapiro; R Daniel; W Brown; A Frost; S O Tabara; K Shah Journal: Sex Transm Dis Date: 1998-05 Impact factor: 2.830
Authors: K L Liaw; A G Glass; M M Manos; C E Greer; D R Scott; M Sherman; R D Burk; R J Kurman; S Wacholder; B B Rush; D M Cadell; P Lawler; D Tabor; M Schiffman Journal: J Natl Cancer Inst Date: 1999-06-02 Impact factor: 13.506
Authors: S Syrjänen; I Shabalova; N Petrovichev; V Kozachenko; T Zakharova; J Pajanidi; J Podistov; G Chemeris; L Sozaeva; E Lipova; I Tsidaeva; O Ivanchenko; A Pshepurko; S Zakharenko; R Nerovjna; L Kljukina; O Erokhina; M Branovskaja; M Nikitina; V Grunberga; A Grunberg; A Juschenko; M Cintorino; R Santopietro; P Tosi; K Syrjänen Journal: Eur J Gynaecol Oncol Date: 2005 Impact factor: 0.196
Authors: L Ahdieh; R S Klein; R Burk; S Cu-Uvin; P Schuman; A Duerr; M Safaeian; J Astemborski; R Daniel; K Shah Journal: J Infect Dis Date: 2001-08-24 Impact factor: 5.226
Authors: Rolando Herrero; Philip E Castle; Mark Schiffman; M Concepción Bratti; Allan Hildesheim; Jorge Morales; Mario Alfaro; Mark E Sherman; Sholom Wacholder; Sabrina Chen; Ana C Rodriguez; Robert D Burk Journal: J Infect Dis Date: 2005-05-02 Impact factor: 5.226
Authors: Nubia Muñoz; F Xavier Bosch; Silvia de Sanjosé; Rolando Herrero; Xavier Castellsagué; Keerti V Shah; Peter J F Snijders; Chris J L M Meijer Journal: N Engl J Med Date: 2003-02-06 Impact factor: 91.245
Authors: A Hildesheim; M H Schiffman; P E Gravitt; A G Glass; C E Greer; T Zhang; D R Scott; B B Rush; P Lawler; M E Sherman Journal: J Infect Dis Date: 1994-02 Impact factor: 5.226
Authors: Anna R Giuliano; Robin Harris; Rebecca L Sedjo; Susie Baldwin; Denise Roe; Mary R Papenfuss; Martha Abrahamsen; Paula Inserra; Sandra Olvera; Kenneth Hatch Journal: J Infect Dis Date: 2002-08-02 Impact factor: 5.226
Authors: S S Wang; M Schiffman; R Herrero; J Carreon; A Hildesheim; A C Rodriguez; M C Bratti; M E Sherman; J Morales; D Guillen; M Alfaro; B Clayman; R D Burk; R P Viscidi Journal: Br J Cancer Date: 2004-10-04 Impact factor: 7.640
Authors: Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Concepción Bratti; Mark E Sherman; Diane Solomon; Diego Guillén; Mario Alfaro; Jorge Morales; Martha Hutchinson; Li Cheung; Sholom Wacholder; Robert D Burk Journal: Int J Cancer Date: 2012-02-28 Impact factor: 7.396
Authors: Long Fu Xi; Zoe R Edelstein; Craig Meyers; Jesse Ho; Stephen L Cherne; Mark Schiffman Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-08-18 Impact factor: 4.254
Authors: Anne F Rositch; Jill Koshiol; Michael G Hudgens; Hilda Razzaghi; Danielle M Backes; Jeanne M Pimenta; Eduardo L Franco; Charles Poole; Jennifer S Smith Journal: Int J Cancer Date: 2012-10-11 Impact factor: 7.396
Authors: Long Fu Xi; James P Hughes; Zoe R Edelstein; Nancy B Kiviat; Laura A Koutsky; Constance Mao; Jesse Ho; Mark Schiffman Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: N Muñoz; G Hernandez-Suarez; F Méndez; M Molano; H Posso; V Moreno; R Murillo; M Ronderos; C Meijer; A Muñoz Journal: Br J Cancer Date: 2009-03-17 Impact factor: 7.640